More on Amgen (AMGN): Q2 beats across the board on a 13% Y/Y jump in total revenue. Product sales growth was driven by strong performance across the portfolio. Xgeva sales total: $179M. For 2012, the company guides higher, now seeing an EPS of $6.20 to $6.35 on revenue of $16.9B to $17.2B. Street estimates are for earnings of $6.15 per share on $16.37B in revenue. Shares +4.4% AH.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs